Elevai Labs (NASDAQ:ELAB) Upgraded to “Hold” at Wall Street Zen

Wall Street Zen upgraded shares of Elevai Labs (NASDAQ:ELAB) from a sell rating to a hold rating in a research report released on Thursday morning.

Elevai Labs Stock Down 6.0%

Shares of ELAB opened at $2.34 on Thursday. The stock has a market capitalization of $2.07 million, a price-to-earnings ratio of -0.04 and a beta of -0.95. Elevai Labs has a 1 year low of $2.14 and a 1 year high of $970.48. The business’s 50 day simple moving average is $3.33 and its 200-day simple moving average is $11.37. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.86 and a quick ratio of 3.40.

Elevai Labs (NASDAQ:ELAB) last issued its quarterly earnings data on Wednesday, May 14th. The company reported ($2.90) earnings per share (EPS) for the quarter. Elevai Labs had a negative return on equity of 124.93% and a negative net margin of 223.41%.

About Elevai Labs

Elevai Labs, Inc, a skincare development company, designs, manufactures, and markets skincare products. Its products include Empower and Enfinity post-skincare procedure care serums for the face, neck, and upper chest regions. The company was formerly known as Reactive Medical Labs Inc and changed its name to Elevai Labs, Inc in December 2021.